Glutathione S-Transferase Deletion Polymorphisms in Early-Onset Psychotic and Bipolar Disorders: A Case-Control Study.
OBJECTIVE
To examine glutathione S-transferase (GST) deletion polymorphisms in development of early-onset severe mental disorders, with the hypothesis that patients with GSTM1-null and GSTT1-null genotypes will develop psychotic disorders at a younger age.


METHODS
We identified GSTM1 and GSTT1 deletion polymorphisms by multiplex polymerase chain reaction (PCR) in 93 patients with early onset severe mental disorders and 278 control individuals. The diagnoses were confirmed by Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version and Schedule for Affective Disorders and Schizophrenia-Life-Time Version (K-SADS-PL) interviews.


RESULTS
Individuals with the GSTM1-null genotype were at 3.36-fold higher risk of developing early-onset severe mental disorders than carriers of a corresponding active genotype. The risk of those disorders was increased by 6.59-fold in patients with GSTM1-null/GSTT1-active genotype. Patients with the GSTM1-null genotype were at approximately 2-fold increased risk for developing early-onset schizophrenia-spectrum disorder (EOS), early-onset bipolar disorder (EOBD) with psychotic symptoms, or early-onset first-episode psychosis (EOFEP), compared with patients with the GSTM1-active genotype.


CONCLUSIONS
The GSTM1-null genotype might be associated with higher risk for early onset severe mental disorders.
Institute of Mental Health, Belgrade, Serbia Faculty of Medicine, University in Belgrade, Belgrade, Serbia.
Milica M
MM
Pejovic-Milovancevic
Institute of Mental Health, Belgrade, Serbia.
Vanja D
VD
Mandic-Maravic
Faculty of Medicine, University in Belgrade, Belgrade, Serbia Institute of Medical and Clinical Biochemistry, Belgrade, Serbia.
Vesna M
VM
Coric
Institute of Mental Health, Belgrade, Serbia.
Marija M
MM
Mitkovic-Voncina
Institute of Mental Health, Belgrade, Serbia.
Milutin V
MV
Kostic
Faculty of Medicine, University in Belgrade, Belgrade, Serbia Institute of Medical and Clinical Biochemistry, Belgrade, Serbia.
Ana R
AR
Savic-Radojevic
Faculty of Medicine, University in Belgrade, Belgrade, Serbia Clinic of Neurology, Clinical Centre of Serbia, Belgrade, Serbia.
Marko D
MD
Ercegovac
Faculty of Medicine, University in Belgrade, Belgrade, Serbia Institute of Medical and Clinical Biochemistry, Belgrade, Serbia.
Marija G
MG
Matic
Institute of Mental Health, Belgrade, Serbia.
Amir N
AN
Peljto
Institute of Mental Health, Belgrade, Serbia Faculty of Medicine, University in Belgrade, Belgrade, Serbia Serbian Academy of Science and Arts, Belgrade, Serbia.
Dusica R
DR
Lecic-Tosevski
Faculty of Medicine, University in Belgrade, Belgrade, Serbia Institute of Medical and Clinical Biochemistry, Belgrade, Serbia.
Tatjana P
TP
Simic
Faculty of Medicine, University in Belgrade, Belgrade, Serbia Institute of Medical and Clinical Biochemistry, Belgrade, Serbia marijaercegovac@med.bg.ac.rs.
Marija S
MS
Pljesa-Ercegovac
D000293:Adolescent; D000328:Adult; D000818:Animals; D016022:Case-Control Studies; D005260:Female; D060005:Genotyping Techniques; D005982:Glutathione Transferase / Q000235:genetics*; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000235:genetics*; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D017384:Sequence Deletion; D055815:Young Adult
D005982:Glutathione Transferase; C413545:glutathione S-transferase T1
bipolar disorder; genetic polymorphisms; glutathione transferases; psychotic disorders; risk factor; schizophrenia